振源胶囊对冠心病伴抑郁患者负性情绪及心功能的影响

Effect of Zhenyuan capsule on negative emotion and heart function in patients with coronary heart disease and depression

目的探究振源胶囊对冠心病伴抑郁患者负性情绪及对心功能的影响。方法回顾性选取2018年7月至2019年4月德州市人民医院收治的冠心病伴抑郁患者167例。根据治疗方法不同分为对照组(n=82)和观察组(n=85)。对照组进行常规治疗和心理干预,观察组在对照组基础上使用振源胶囊治疗。观察2组患者治疗3个月后临床疗效、心功能疗效,治疗前与治疗3个月后的抑郁状态、炎症因子[白细胞介素6(IL-6),肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hs-CRP)]水平及不良反应情况。结果治疗3个月后,观察组治疗总有效率为88.24%,高于对照组的68.29%,差异有统计学意义(P<0.05);观察组心功能总有效率92.94%,高于对照组的69.51%,差异有统计学意义(P<0.05)。治疗前,2组HAMD评分比较,差异无统计学意义(P>0.05);治疗3个月后,观察组HAMD评分为(12.08±2.84)分,低于对照组[(15.60±2.97)分],差异有统计学意义(P<0.05)。治疗前,2组患者血清IL-6、TNF-α及hs-CRP水平比较,差异无统计学意义(P>0.05);治疗3个月后,观察组血清IL-6、TNF-α及hs-CRP水平分别为(12.17±4.35)pg/mL、(1.08±0.58)ng/mL、(12.18±4.27)mg/L,均低于对照组[(15.12±3.38)pg/mL、(1.70±0.68)ng/mL、(18.61±6.46)mg/L],差异均有统计学意义(P<0.05)。安全性方面,2组患者在治疗过程中未出现心力衰竭、心肌梗死、血压、血糖升高、心动过缓、室性早搏及房颤等不良反应。结论振源胶囊治疗冠心病伴抑郁患者可提高心功能疗效,改善抑郁状态,减轻炎性反应,临床疗效较好,具有较好应用前景。

Objective To explore the effect of Zhenyuan Capsule on negative emotion and heart function in patients with coronary heart disease and depression.Methods A total of 167 patients with coronary heart disease and depression admitted to Dezhou People's Hospital from July 2018 to April 2019 were retrospectively selected and divided into control group(n=82)and observation group(n=85)by different treatment methods.The control group received conventional treatment and psychological intervention,and the observation group was supplemented with Zhenyuan capsule.The clinical efficacy and cardiac function efficacy after 3 months of treatment,depression and inflammatory factors[interleukin 6(IL-6),tumor necrosis factor-α(TNF-α),high sensitivity C-reactive protein(hs-CRP)]levels before and after 3 months of treatment and adverse reactions were observed between the two groups.Results After 3 months of treatment,the total effective rate of treatment in the observation group was 88.24%,which was higher than 68.29%in the control group,the difference was statistically significant(P<0.05).The total effective rate of cardiac function in the observation group was 92.94%,which was higher than that 69.51%in the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in HAMD scores between the two groups(P>0.05);after 3 months of treatment,the HAMD score in the observation group was(12.08±2.84)points,which were lower than those in the control group[(15.60±2.97)points],the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in serum IL-6,TNF-αand hs-CRP levels between the two groups of patients(P>0.05);after 3 months of treatment,the levels of serum IL-6,TNF-αand hs-CRP in the observation group were(12.17±4.35)pg/mL,(1.08±0.58)ng/mL,(12.18±4.27)mg/L,which all lower than those in the control group[(15.12±3.38)pg/mL,(1.70±0.68)ng/mL,(18.61±6.46)mg/L],the differences were statistically significant(P<0.05).In terms of safety,the two groups of patients had no adverse reactions such as heart failure,myocardial infarction,blood pressure,elevated blood sugar,bradycardia,ventricular premature beats,and atrial fibrillation during the treatment.Conclusion Zhenyuan capsule can improve cardiac function and depression,and reduce inflammatory response in patients with coronary heart disease and depression.Therefore,it has good clinical effect and good application prospects.